Thymosin Alpha-1 news and clinical trials

Fudan University registered a phase II clinical trial to evaluate the safety and efficacy of thymalfasin combined with chemotherapy and immunotherapy in 572 patients with triple-negative breast cancer. The study will compare 3-year event-free survival between treatment groups.

Shanghai Zhongshan Hospital registered a randomized, controlled trial to test if adding 1.6 mg of thymalfasin twice daily for 7 days improves immune recovery in 60 adults with sepsis and immune function impairment.

A scoping review of 26 clinical publications characterized the use of Thymosin Alpha 1 as an adjunctive cancer therapy, finding it is most commonly administered via subcutaneous injection and used alongside various anticancer treatments, though standardized prospective studies are needed.

A randomized controlled trial showed that Phellinus igniarius decoction effectively restored immune function and improved quality of life in colorectal cancer patients following chemotherapy, with patients suffering from spleen-kidney deficiency syndrome responding best.

Researchers identified that Thymosin Alpha 1 acts as a non-canonical ligand for the Hypocretin Receptor 1, protecting neurons from cell death in ischemic stroke models by suppressing the activity of Receptor-Interacting Protein Kinase 3.

The Affiliated Hospital of Putian University registered a Phase 2 trial for 31 patients to explore the efficacy and safety of combining adebrelimab, thymalfasin, and chemotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma.

Nanjing Medical University completed a 600-participant study testing the hypothesis that administering thymosin alpha 1 during the acute phase of aortic dissection surgery reduces the incidence of systemic inflammatory response syndrome and multiple organ dysfunction syndrome.

Sun Yat-sen University completed a Phase 2 randomized study evaluating the impact of thymosin alpha 1 on patient survival, treatment response, and toxicity in locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by immunotherapy.

Fakih IVF Fertility Center registered a Phase 2/3 trial to evaluate the safety and efficacy of Thymosin-α1 as an adjunctive immunomodulatory therapy for 136 women with recurrent implantation failure undergoing IVF cycles.

An in vitro study found that Thymosin Alpha 1 enhances the proliferation and activation of CD8+ T cells while reducing the expression of exhaustion markers like PD-1, TIM-3, and LAG-3 following chronic stimulation.

A study found that Thymosin Alpha 1 functions as a microRNA chaperone in dendritic cells, protecting miR-146a-5p from degradation to enhance TLR7-mediated activation of tumor-specific CD8+ T cells and improve chemotherapy outcomes.

Sun Yat-sen University registered a Phase 2 open-label trial to evaluate the effectiveness and safety of combining Thymosin Alpha 1 with a PD-1 monoclonal antibody in 55 elderly patients with advanced melanoma.

An Integrative Medicine review evaluated the use of peptides for thyroid disorders, finding that current evidence for agents like BPC-157 and thymosin is largely limited to preclinical studies and exploratory reports rather than large randomized trials.

Beijing Friendship Hospital completed a retrospective controlled study involving 47 participants to investigate the efficacy and safety of combining neoadjuvant chemoradiotherapy with a PD-1 inhibitor and thymalfasin for locally advanced mid-low rectal cancer.

A phase II trial of 34 patients with bulky solid tumors evaluated spatially fractionated radiotherapy combined with immune checkpoint inhibitors and anti-angiogenic agents. The study reported an objective response rate of 65.63% and observed abscopal effects in 22.73% of evaluable patients.

Researchers led by William B. Ershler, MD, completed a Phase 2 pilot trial involving 189 renal dialysis patients to test if Thymosin Alpha 1 administration can prevent COVID-19 infection in this high-risk population.

New paper in Pakistan journal of medical sciences: Thymalfasin combined with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: A retrospective study on efficacy, safety, and immunological function.

Researchers demonstrated that combining interleukin-15 and Thymosin Alpha 1 suppresses tumor growth in hepatocellular carcinoma models by reversing CD8+ T cell senescence through the suppression of the PI3K/AKT signaling pathway.

In a phase II trial of 30 patients with locally advanced gastric cancer, researchers found that neoadjuvant treatment with serplulimab, SOX, and thymalfasin achieved a pathological complete response of 30.0%. The regimen showed an acceptable safety profile with encouraging nodal clearance.

Clinicians reported a case of a nasopharyngeal carcinoma patient who developed multisystem immune-related adverse events after treatment with sintilimab combined with thymosin alpha-1. The report advises clinical vigilance regarding potential immune overactivation from this combination therapy.

Nanjing Medical University registered a multicenter randomized controlled trial involving 300 patients to test if AI-assisted immunoinflammatory subtyping can guide precision treatment with ulinastatin and thymalfasin in acute aortic dissection cases.

The First Affiliated Hospital with Nanjing Medical University registered a phase 2 trial to evaluate the efficacy and safety of Thymosin Alpha 1 combined with serplulimab and chemoradiotherapy in 48 patients with stage III gastroesophageal junction adenocarcinoma.

A review article discussed how thymosin alpha-1 acts as an immunomodulator that helps restore immune function in the elderly by stimulating T-cell differentiation. The article notes that the fusion drug Refnot is a promising therapeutic approach for age-related immune decline.